Psychiatry

Patients with depression from high-wealth areas were 1.62 times more likely in primary care and 1.67 times more likely in psychiatry to use telehealth.

The FDA accepted the sNDA for risperidone (Uzedy) extended-release injectable suspension for the maintenance treatment of bipolar I disorder in adults.

Comorbid conditions accrued at a rate 30% faster among adults with depression than in those without the disorder over a 7-year follow-up period.

People with MDD demonstrated a preference for carbohydrate-rich foods and reduced reward from fat- and protein-rich foods, according to new research.

The first patient was dosed in the Panorama study assessing MM120 ODT, a form of LSD, for the treatment of GAD.

GH001, an inhalable 5-MeO-DMT therapy, led to a -15.5 MADRS score reduction by day 8 in patients with treatment-resistant depression.

Brexpiprazole and sertraline showed promise for PTSD treatment in a recent study. Lead author, Lori Davis, MD, discusses clinical findings, treatment guidelines, and future research directions.

Your daily dose of the clinical news you may have missed.

Data showed that brexpiprazole plus sertraline significantly improved PTSD symptoms vs sertraline alone. Lead author, Lori Davis, MD, discusses more.

The investigational and potentially first-in-class therapy may enhance AMPA receptor sensitivity to glutamate, enhancing neuronal transmission.